Pleuropericarditis Related to the Use of Mesalamine

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 1996 Mar 1

PMID 8617147

Citations 14

Authors

N Gujral

F Friedenberg

J Friedenberg

G Gabriel

M Kotler

G Levine

Affiliations

Soon will be listed here.

Citing Articles

Incidence, Predictors, and Outcomes of Acute Pericarditis in Patients with Inflammatory Bowel Disease: A 10-Year Nationwide Analysis.

Agrawal A, Bayat A, Bhagat U, Wassif H, Klein A, Garshick M CJC Open. 2024; 6(11):1379-1385.

PMID: 39582700 PMC: 11583852. DOI: 10.1016/j.cjco.2024.08.004.

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity.

Chen J, Duan T, Fang W, Liu S, Wang C Front Pharmacol. 2022; 13:970597.

PMID: 36188558 PMC: 9520406. DOI: 10.3389/fphar.2022.970597.

Successful Treatment with Corticosteroids in an 11-Year-Old Patient with Crohn's Disease and Myopericarditis-Case Report.

Ryzko J, Zdanowicz K, Lebensztejn D, Daniluk U Pediatr Rep. 2022; 14(1):26-31.

PMID: 35076578 PMC: 8788440. DOI: 10.3390/pediatric14010005.

Cardiovascular Manifestations in Inflammatory Bowel Disease: A Systematic Review of the Pathogenesis and Management of Pericarditis.

Patel R, Rohit Reddy S, Llukmani A, Hashim A, Haddad D, Patel D Cureus. 2021; 13(3):e14010.

PMID: 33884251 PMC: 8054944. DOI: 10.7759/cureus.14010.

Mesalamine-Induced Myopericarditis: A Case Report and Literature Review.

Taha M, Abdalla A, Al-Khafaji J, Malik S Cardiol Res. 2019; 10(1):59-62.

PMID: 30834061 PMC: 6396800. DOI: 10.14740/cr820.

References

Deboever G, Devogelaere R, Holvoet G . Sulphasalazine-induced lupus-like syndrome with cardiac tamponade in a patient with ulcerative colitis. Am J Gastroenterol. 1989; 84(1):85-6. View

Jenss H, Becker E, Weber P . Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease. Am J Gastroenterol. 1990; 85(3):332-3. View

Clementz G, Dolin B . Sulfasalazine-induced lupus erythematosus. Am J Med. 1988; 84(3 Pt 1):535-8. DOI: 10.1016/0002-9343(88)90279-3. View

Schroder H, Campbell D . Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972; 13(4):539-51. DOI: 10.1002/cpt1972134539. View

Agnholt J, Sorensen H, Rasmussen S, Gotzsche C, Halkier P . Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet. 1989; 1(8647):1135. DOI: 10.1016/s0140-6736(89)92407-0. View

Miner P, Hanauer S, Robinson M, Schwartz J, Arora S . Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995; 40(2):296-304. DOI: 10.1007/BF02065413. View

Carr-Locke D . Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease. Am J Gastroenterol. 1982; 77(9):614-6. View

Kristensen K, Hoegholm A, Bohr L, Friis S . Fatal myocarditis associated with mesalazine. Lancet. 1990; 335(8689):605. DOI: 10.1016/0140-6736(90)90387-k. View

Das K, Dubin R . Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet. 1976; 1(6):406-25. DOI: 10.2165/00003088-197601060-00002. View

10.

Sandberg-Gertzen H, Jarnerot G, Tysk C . Long-term treatment with olsalazine for ulcerative colitis: safety and relapse prevention: a follow-up study. Scand J Gastroenterol Suppl. 1988; 148:48-50. DOI: 10.3109/00365528809101548. View

11.

Patwardhan R, Heilpern R, Brewster A, Darrah J . Pleuropericarditis: an extraintestinal complication of inflammatory bowel disease. Report of three cases and review of literature. Arch Intern Med. 1983; 143(1):94-6. View